导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.19% | 3425/4773 |
| 近一周 | -1.68% | 2516/5465 |
| 近一月 | -7.75% | 4669/5421 |
| 近一季 | 6.28% | 264/5231 |
| 近半年 | -5.77% | 3087/4920 |
| 近一年 | -15.33% | 3726/4394 |
| 近两年 | 19.39% | 2665/2954 |
| 近三年 | -7.19% | 2006/2253 |
| 成立以来 | 53.20% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.53% 1841/4961 |
-7.88% 3811/5312 |
- - |
- - |
| 2025 | 7.21% 2933/4813 |
2.71% 1283/3635 |
3.29% 1066/4076 |
10.13% 3320/4524 |
-8.24% 3891/4813 |
| 2024 | -10.06% 2336/3463 |
-10.28% 2332/2808 |
-7.29% 2066/3014 |
16.99% 1296/3129 |
-7.57% 2775/3463 |
| 2023 | -9.48% 1169/2656 |
1.92% 1484/2280 |
-8.35% 1987/2385 |
-2.67% 718/2515 |
-0.43% 213/2655 |
| 2022 | -17.36% 581/2207 |
-12.56% 636/1919 |
-0.53% 1632/2016 |
-13.71% 955/2113 |
10.11% 182/2208 |
| 2021 | 1.92% 648/1822 |
-0.83% 395/1255 |
12.14% 346/1330 |
-10.81% 1241/1466 |
2.74% 528/1822 |
| 2020 | 42.11% 277/1250 |
8.66% 30/1028 |
29.56% 71/1067 |
2.13% 1010/1164 |
-1.16% 1094/1184 |
| 2019 | 28.76% 515/1092 |
25.56% 455/754 |
-7.35% 554/804 |
6.00% 133/850 |
4.42% 801/918 |
| 2018 | -25.69% 362/834 |
- - |
- - |
- - |
-14.29% 575/691 |
| 2017 | 0.79% 469/714 |
- - |
- - |
- - |
- - |
| 2016 | -14.22% 335/605 |
- - |
- - |
- - |
- - |
| 2015 | 51.59% 18/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国联安中证医药100A VS. 长安沪深300非周期A(740101) |